Preliminary report on therapeutic potential of coal-derived carbon quantum dots against SARS-CoV-2 virus
Copyright © 2024 Elsevier Inc. All rights reserved..
Due to the pandemic of COVID-19 and subsequent emerging of new mutant strains, there has been a worldwide hunt for therapeutic and protective agents for its inhibition. In this short communication, for the first time, we report the coal-derived carbon quantum dot (CQD) for the possible therapeutic application against SARS-CoV-2. The synthesized C1-CQD is observed to be safe towards the normal cell line at highest dose, while effectively inhibiting growth of SARS-CoV2 (>95%) with IC50 value of 5.469 μg/mL. Moreover, C1-CQD showed activity against SARS-CoV-2 infection which is comparable to known inhibitory antiviral drug i.e., Remdesivir. These novel findings indicate that coal-based CQDs have highly potent anti-viral activity and could be investigated further for developing cheap and safer alternative therapeutic strategies for inhibition of SARS-CoV-2.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:593 |
|---|---|
| Enthalten in: |
Virology - 593(2024) vom: 29. März, Seite 110036 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Saikia, Binoy K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7440-44-0 |
|---|
| Anmerkungen: |
Date Completed 13.03.2024 Date Revised 13.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.virol.2024.110036 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369219228 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369219228 | ||
| 003 | DE-627 | ||
| 005 | 20240313234606.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240304s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.virol.2024.110036 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM369219228 | ||
| 035 | |a (NLM)38432047 | ||
| 035 | |a (PII)S0042-6822(24)00057-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Saikia, Binoy K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preliminary report on therapeutic potential of coal-derived carbon quantum dots against SARS-CoV-2 virus |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.03.2024 | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Inc. All rights reserved. | ||
| 520 | |a Due to the pandemic of COVID-19 and subsequent emerging of new mutant strains, there has been a worldwide hunt for therapeutic and protective agents for its inhibition. In this short communication, for the first time, we report the coal-derived carbon quantum dot (CQD) for the possible therapeutic application against SARS-CoV-2. The synthesized C1-CQD is observed to be safe towards the normal cell line at highest dose, while effectively inhibiting growth of SARS-CoV2 (>95%) with IC50 value of 5.469 μg/mL. Moreover, C1-CQD showed activity against SARS-CoV-2 infection which is comparable to known inhibitory antiviral drug i.e., Remdesivir. These novel findings indicate that coal-based CQDs have highly potent anti-viral activity and could be investigated further for developing cheap and safer alternative therapeutic strategies for inhibition of SARS-CoV-2 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-viral | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Carbon quantum dot | |
| 650 | 4 | |a Coal | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Toxicity | |
| 650 | 4 | |a Viral replication | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Carbon |2 NLM | |
| 650 | 7 | |a 7440-44-0 |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 700 | 1 | |a Roy, Kallol |e verfasserin |4 aut | |
| 700 | 1 | |a Konwar, Rituraj |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Virology |d 1955 |g 593(2024) vom: 29. März, Seite 110036 |w (DE-627)NLM000011347 |x 1096-0341 |7 nnns |
| 773 | 1 | 8 | |g volume:593 |g year:2024 |g day:29 |g month:03 |g pages:110036 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.virol.2024.110036 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 593 |j 2024 |b 29 |c 03 |h 110036 | ||